You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

 

CME / ABIM MOC / CE

Leptomeningeal Carcinomatosis and EGFR-Mutated Advanced NSCLC: A Fork in the Road

  • Authors: Seema Nagpal, MD
  • CME / ABIM MOC / CE Released: 6/21/2019
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 6/21/2020, 11:59 PM EST
Start Activity


Target Audience and Goal Statement

This activity is intended for oncology specialists, pulmonologists, pathologists, and nurses.

The goal of this activity is to educate clinicians treating patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) on optimal strategies for diagnosis and management of leptomeningeal carcinomatosis (LMC).

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Clinical trial data on LMC in patients with EGFR-mutated advanced NSCLC
  • Have greater competence related to
    • Identifying the most appropriate regimen for a patient who presents with LMC and EGFR-mutated advanced NSCLC
    • Managing treatment-related adverse events (TRAEs)


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Faculty

  • Seema Nagpal, MD

    Clinical Associate Professor
    Stanford University
    Stanford, California

    Disclosures

    Disclosure: Seema Nagpal, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AbbVie Inc.; GW Pharmaceuticals plc; Kiyatec, Inc.; Tocagen
    Received grants for clinical research from: Berg LLC

Editors

  • Elaine Hamarstrom, PhD

    Medical Education Director, Medscape, LLC

    Disclosures

    Disclosure:  Elaine Hamarstrom, PhD, has disclosed no relevant financial relationships.

  • Tristin Abair, PhD

    Medical Writer, Medscape, LLC

    Disclosures

    Disclosure:  Tristin Abair, PhD, has disclosed no relevant financial relationships.

CME Reviewer

  • Esther Nyarko, PharmD

    Associate Clinical CME Director, Medscape, LLC

    Disclosures

    Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Boehringer Ingelheim Pharmaceuticals, Inc.; Ipsen Pharma


Accreditation Statements

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Medscape, LLC staff have disclosed that they have no relevant financial relationships.

    Contact This Provider

    For Nurses

  • Awarded 1.0 contact hour(s) of continuing nursing education for RNs and APNs; 1.0 contact hours are in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Leptomeningeal Carcinomatosis and EGFR-Mutated Advanced NSCLC: A Fork in the Road

Authors: Seema Nagpal, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC / CE Released: 6/21/2019

Valid for credit through: 6/21/2020, 11:59 PM EST

processing....

The following cases are modeled on the interactive grand rounds approach. The questions within the activity are designed to test your current knowledge. After each question, you will be able to see whether you answered correctly and read evidence-based information that supports the most appropriate answer choice. The questions are designed to challenge you; you will not be penalized for answering the questions incorrectly. At the end of the activity, there will be a short post-test assessment based on the material presented.

The goal of this activity is to educate clinicians treating patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) on optimal strategies for diagnosis and management of leptomeningeal carcinomatosis (LMC).

Case 1: Patient History and Presentation

Steven is a 62-year-old never smoker who was diagnosed with stage IV adenocarcinoma of the lung. Computed tomography (CT) showed a right upper lobe mass and bone metastases with no central nervous system (CNS) metastases. Genotyping showed epidermal growth factor receptor (EGFR) exon 21 L858R mutation. He received first-line osimertinib (80 mg daily) and tolerated therapy well, demonstrating a partial response. Six months later, he comes in for a follow-up visit and is complaining of progressively worse headaches each morning and occasional unexplained nausea and vomiting. You suspect he has developed CNS metastases or leptomeningeal carcinomatosis (LMC).

  • Print